BURLINGTON, Mass., [April 15th, 2026] — VentiraDx today announced that the company will participate in the 2026 American Urological Association (AUA) Annual Meeting, taking place May 15–18, 2026, in Washington, D.C.
At AUA 2026, VentiraDx will highlight TAGMeTM, its urine-based DNA methylation assay designed to support non-invasive longitudinal surveillance for urothelial carcinoma recurrence. TAGMeTM is being advanced to address a major clinical need in post-treatment surveillance, where patients often require repeated follow-up and current approaches can be invasive or have limited sensitivity in certain disease settings.
TAGMeTM is designed to provide a urine-based, non-invasive monitoring approach for patients at risk of recurrence, with the goal of supporting earlier detection of recurrence signals and more personalized follow-up strategies. The assay is based on a bisulfite-free methylation qPCR workflow intended to simplify laboratory operations and support scalable testing.
VentiraDx welcomes opportunities to connect with:
CLIA-certified laboratories
interested in evaluation, validation, and potential LDT deployment
Urologists and uro-oncology specialists
interested in clinical adoption, collaboration, and real-world evidence generation
Biopharma partners
exploring biomarker strategies and urothelial carcinoma monitoring applications
Academic investigators and study collaborators
interested in multicenter validation and translational research
During the meeting, attendees are invited to schedule a face-to-face discussion with the VentiraDx team, including the company’s CTO, to explore TAGMe's scientific foundation, clinical rationale, and U.S. collaboration opportunities.
“We look forward to meeting with clinical, laboratory, and industry partners at AUA 2026,” said Dr. Yuker Wang, CTO at VentiraDx. “Our goal is to build meaningful collaborations around non-invasive surveillance tools that may help improve follow-up strategies for patients with urothelial carcinoma.”
To arrange an in-person meeting during AUA 2026, please contact:
Dr. Yuke Wang
Email: info@VentiraDx.com
Phone: (781) 230-6883
Website: www.ventiradx.com
About TAGMeTM
TAGMeTM is a urine-based DNA methylation assay developed for urothelial carcinoma surveillance and recurrence monitoring. The assay is intended to support non-invasive longitudinal follow-up using methylation-based detection technology.
Regulatory Notice
TAGMeTM has received FDA Breakthrough Device Designation, which does not mean FDA clearance or approval. TAGMeTM is not FDA-cleared.